Kiniksa Pharmaceuticals International PLC (NAS:KNSA)
$ 22.58 0.97 (4.49%) Market Cap: 1.61 Bil Enterprise Value: 1.34 Bil PE Ratio: 205.27 PB Ratio: 3.70 GF Score: 62/100

Q4 2021 Kiniksa Pharmaceuticals Ltd Earnings Call Transcript

Feb 22, 2022 / 01:30PM GMT
Release Date Price: $10.62 (-0.93%)
Operator

Thank you for standing by, and welcome to the Kiniksa Pharmaceuticals Fourth Quarter and Full Year 2021 Earnings Conference Call and Corporate Update.

(Operator Instructions)

As a reminder, today's program may be recorded. I would now like to introduce your host for today's program, Rachel Frank, Investor Relations. Please go ahead.

Rachel Frank
Kiniksa Pharmaceuticals, Ltd. - Associate Director of IR

Thank you, operator. Good morning, everyone, and thank you for joining Kiniksa's call to discuss our fourth quarter and full year 2021 financial results and corporate update. A press release highlighting these results can be found on our website under the Investors & Media section. As for the agenda, our Chief Executive Officer, Sanj K. Patel, will start with an introduction. Ross Moat, our Chief Commercial Officer, will provide an update on our ARCALYST commercial execution. Eben Tessari, Kiniksa's Chief Operating Officer, will follow with a brief review of our recently announced strategic collaboration as well as our portfolio. Then Mark

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot